Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

BACKGROUND: Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative malignancies (MPM) (20 chronic myeloid leukemias and 30 myeloproliferative neoplasms), all...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Pimpinelli, Fulvia, Marchesi, Francesco, Piaggio, Giulia, Giannarelli, Diana, Papa, Elena, Falcucci, Paolo, Pontone, Martina, Di Martino, Simona, Laquintana, Valentina, La Malfa, Antonia, Di Domenico, Enea Gino, Di Bella, Ornella, Falzone, Gianluca, Ensoli, Fabrizio, Vujovic, Branka, Morrone, Aldo, Ciliberto, Gennaro, Mengarelli, Andrea
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128283/
https://ncbi.nlm.nih.gov/pubmed/34001183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01090-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados